Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine.
Langerhans-cell histiocytosis (LCH) is a rare condition with a wide clinical spectrum and variable prognosis. Patients with multisystem LCH have been treated with a variety of agents but may develop resistant and progressive disease. Based on a preliminary encouraging report on the activity of 2 chlorodoxyadenosine in this disease, we administered this agent to a patient with LCH which was resistant to corticosteroids and etoposide. After 4 courses of treatment the patient achieved a complete remission which is currently ongoing for 12 months. 2 CdA appears to be effective in patients with resistant LCH and warrants investigation in previously untreated patients with poor risk disease.
Dimopoulos
M A
MA
University of Athens School of Medicine, Department of Clinical Therapeutics, Alexandra Hospital, Greece.
Theodorakis
M
M
Kostis
E
E
Papadimitris
C
C
Moulopoulos
L A
LA
Anastasiou-Nana
M
M
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use*; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy*; D006801:Humans
D000964:Antimetabolites, Antineoplastic; D017338:Cladribine